Navigation Links
Venaxis to Present at Canaccord Genuity 33rd Annual Growth Conference
Date:8/8/2013

CASTLE ROCK, Colo., Aug. 8, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Canaccord Genuity 33rd Annual Growth Conference, to be held August 14-15, 2013, at the Intercontinental Boston in Boston, MA. 

Steve Lundy, President and CEO of Venaxis, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.  Event:Canaccord Genuity 33rd Annual Growth ConferenceDate: Wednesday, August 14, 2013 Time: 11:30 am (Eastern Time) Location:Vancouver Room; Intercontinental Boston; BostonThe presentation will be webcast live.  To access the webcast, please visit the investor relations section of the Venaxis website at http://ir.venaxis.com.  The webcast replay will remain available for 90 days following the live presentation.

About Venaxis, Inc. 
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, protein biomarker-based assay for appendicitis.  This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  The APPY1 Test is being developed initially for pediatric, adoles
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of Directors
2. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
3. Venaxis to Present at 25th Annual ROTH Conference
4. Venaxis Presentation Rescheduled for 2013 BIO CEO and Investor Conference
5. Venaxis to Present at 2013 BIO CEO and Investor Conference
6. AspenBio Pharma Changes Company Name to Venaxis, Inc.
7. TANDEM DIABETES CARE BECOMES PRESENTING SPONSOR OF THE GREATEST AWARDS SHOW IN DIABETES
8. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
9. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
10. Hologic to Present at Two Upcoming Investor Conferences
11. Genomic Health to Present at the Canaccord Genuity 33rd Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 /CNW/ -   ... recalled after Health Canada tests confirmed it contains two ... (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health Distribution of ... product from retail stores across Canada ... including for weight loss and increased energy. ...
(Date:12/24/2014)... 2014  Novastem, a leader in regenerative medicine, ... its study for ischemic stroke at Clinica Santa ... strokes account for 87 percent of all stroke ... the study, entitled "Internal Research Protocol in Combination ... Cells and Intrathecal Administration of Neural Stem Cells ...
(Date:12/24/2014)... Dec. 24, 2014  Actavis plc (NYSE: ... has received a complete response letter from the ... New Drug Application (NDA) for the fixed-dose combination ... of hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... in the receipt of a complete response letter, ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... Breast-Specific Gamma Imaging (BSGI) has been proven to be ... carcinoma in situ (DCIS), a difficult to diagnose breast cancer. ... lesions independent of tissue density and discover very early stage ... of the Radiological Society of North America (RSNA), BSGI is ...
... Nov. 30 Covance Inc. (NYSE: CVD ) today ... Health Care Conference on Wednesday, December 2, 2009 at 1:30 p.m. ... at www.covance.com . In order to register and download ... with headquarters in Princeton, New Jersey, is one of the world,s ...
Cached Medicine Technology:Breast-Specific Gamma Imaging Proves Highly Sensitive for the Detection of Ductal Carcinoma In Situ 2
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and ... under $150 . All these items are brand new; they ... already been updated with the new range of high quality ... far. All iFitDress.com’s designs are made according to the latest ... materials. Every outfit from the company is handpicked by skilled ...
(Date:12/24/2014)... December 24, 2014 Risperdal lawsuit ( ... mass tort litigation currently underway in Pennsylvania’s Philadelphia Court ... of December 24, 2014, court documents indicate that 1,183 ... of individuals who developed gynecomastia (male breast growth) and ... the Court indicates that this represents an increase of ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 New studies reveal ... to hearing loss related depression (March 6, 2014, JAMA Otolaryngology*). ... gradual hearing loss (about 50 percent according to recent polls) ... effect on how a person feels and relates to the ... overall improvements are also made by way of:, ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Dr. Vu ... the expansion of his practice and med-spa with the ... practice’s growing list of cosmetic treatments and services. , ... into the skin,” says Dr. Ho. “As a result ... such as wrinkles, sun spots, discolorations or blemishes.” , ...
(Date:12/24/2014)... December 24, 2014 The federal ... allege the blood thinner caused life-threatening episodes of ... leadership structure for the proceeding, Bernstein Liebhard LLP ... the Court plans to select lawyers to serve ... plans on appointing a Plaintiffs’ Steering Committee, which ...
Breaking Medicine News(10 mins):Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3
... April 4, 2008 Companies align,commercial and portfolio ... an annual sales volume of $10 to 20 ... the early-stage commercialization team along,with approximately eight portfolio ... is approximately four to three, commercial to,portfolio management ...
... Lilly and Company,(NYSE: LLY ) today announced ... for FORSTEO(R) (teriparatide [rDNA origin] injection) for the,treatment ... women and men at increased risk for fracture.,This ... February by,the Committee for Medicinal Products for Human ...
... 3, 2008 To promote,the U.S. Department ... for a,Healthy Future" initiative, Acting U.S. Surgeon ... visited with several community leaders at A.I.,DuPont ... in reducing,childhood obesity in Delaware., (Photo: ...
... Targeted mass,media campaigns alone can be effective ... to adopt safer,sex practices, according to a ... the University of Kentucky with funding from ... public health campaigns, particularly those promoting healthy,behaviors, ...
... Security determined outcome of ,terrible 2s, battles but not ... News) -- The way mothers and their 2-year-olds relate ... the frequency -- of conflict during the "terrible twos." ... quality and frequency of such conflicts, according to a ...
... Plus, meet and greet fitness and figure professionals, PITTSBURGH, April 3, 2008 , ... Frahn WHAT: The MORE ... of the More Magazine Marathon and Half-Marathon) WHEN: 12 -7 p.m. April ... 135 W. 18th Street, New York (between 6th and 7th ...
Cached Medicine News:Health News:Early-stage Commercialization Success: Pharma Companies Adjust Resources in Light of Industry Changes 2Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 2Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 3Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 4Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 5Health News:Delaware's Campaign to Make Kids Healthy Gets Boost from US Top Doc 2Health News:Delaware's Campaign to Make Kids Healthy Gets Boost from US Top Doc 3Health News:Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults 2Health News:Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults 3Health News:Mother-Child Bond Affects Quality of Conflict Resolution 2Health News:GNC to Run Sweepstakes, Raffle Fitness Equipment at MORE Magazine Health and Wellness Expo 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: